000182812 001__ 182812
000182812 005__ 20240229145732.0
000182812 0247_ $$2doi$$a10.3389/fonc.2022.1002360
000182812 0247_ $$2pmid$$apmid:36439508
000182812 0247_ $$2pmc$$apmc:PMC9682265
000182812 037__ $$aDKFZ-2022-02944
000182812 041__ $$aEnglish
000182812 082__ $$a610
000182812 1001_ $$aLei, Huijun$$b0
000182812 245__ $$aOverview on population screening for carriers with germline BRCA mutation in China.
000182812 260__ $$aLausanne$$bFrontiers Media$$c2022
000182812 3367_ $$2DRIVER$$aarticle
000182812 3367_ $$2DataCite$$aOutput Types/Journal article
000182812 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1669737762_22674$$xReview Article
000182812 3367_ $$2BibTeX$$aARTICLE
000182812 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182812 3367_ $$00$$2EndNote$$aJournal Article
000182812 520__ $$aCarriers with BRCA1/2 germline pathogenic variants are associated with a high risk of breast and ovarian cancers (also pancreatic and prostate cancers). While the spectrum on germline BRCA mutations among the Chinese population shows ethnic specificity, the identification of carriers with germline BRCA mutation before cancer onset is the most effective approach to protect them. This review focused on the current status of BRCA1/2 screening, the surveillance and prevention measures, and discussed the issues and potential impact of BRCA1/2 population screening in China. We conducted literature research on databases PubMed and Google Scholar, as well as Chinese databases CNKI and Wangfang Med Online database (up to 31 March 2022). Latest publications on germline BRCA1/2 prevalence, spectrum, genetic screening as well as carrier counseling, surveillance and prevention were captured where available. While overall 15,256 records were retrieved, 72 publications using germline BRCA1/2 testing were finally retained for further analyses. Germline BRCA1/2 mutations are common in Chinese patients with hereditary breast, ovarian, prostate and pancreatic cancers. Within previous studies, a unique BRCA mutation spectrum in China was revealed. Next-generation sequencing panel was considered as the most common method for BRCA1/2 screening. Regular surveillance and preventive surgeries were tailored to carriers with mutated-BRCA1/2. We recommend that all Chinese diagnosed with breast, ovarian, pancreatic or prostate cancers and also healthy family members, shall undergo BRCA1/2 gene test to provide risk assessment. Subsequently, timely preventive measures for mutation carriers are recommended after authentic genetic counseling.
000182812 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000182812 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182812 650_7 $$2Other$$aBRCA
000182812 650_7 $$2Other$$aChina
000182812 650_7 $$2Other$$afamilial risk
000182812 650_7 $$2Other$$agermline mutation
000182812 650_7 $$2Other$$apopulation screening
000182812 7001_ $$aZhang, Min$$b1
000182812 7001_ $$aZhang, Luyao$$b2
000182812 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b3$$udkfz
000182812 7001_ $$aWang, Xiao-Jia$$b4
000182812 7001_ $$aChen, Tianhui$$b5
000182812 773__ $$0PERI:(DE-600)2649216-7$$a10.3389/fonc.2022.1002360$$gVol. 12, p. 1002360$$p1002360$$tFrontiers in oncology$$v12$$x2234-943X$$y2022
000182812 909CO $$ooai:inrepo02.dkfz.de:182812$$pVDB
000182812 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000182812 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000182812 9141_ $$y2022
000182812 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-01-27
000182812 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000182812 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000182812 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-27
000182812 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-27
000182812 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT ONCOL : 2021$$d2022-11-08
000182812 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-08
000182812 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-08
000182812 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T13:25:45Z
000182812 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T13:25:45Z
000182812 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-11T13:25:45Z
000182812 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-08
000182812 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-08
000182812 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-08
000182812 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT ONCOL : 2021$$d2022-11-08
000182812 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000182812 980__ $$ajournal
000182812 980__ $$aVDB
000182812 980__ $$aI:(DE-He78)C020-20160331
000182812 980__ $$aUNRESTRICTED